Prostate Cancer Archives - Medical Conferences

Combination of radium-223 and enzalutamide benefits patients with mCRPC with bone metastases

Presented By

Prof. Silke Gillessen, Oncology Institute of Southern Switzerland

Trial

Phase 3, PEACE-3

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:38

177Lu-PSMA effective both in mCRPC and mHSPC

Presented By

Prof. Oliver Sartor, Tulane University, LA, USA; Dr Arun Azad, Peter MacCallum Cancer Centre, Australia

Trial

SPLASH, UpFrontPSMA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:35

Decipher score is predictive for docetaxel-benefit in mestastatic prostate cancer

Presented By

Dr Emily Grist, University College London, UK

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:33

Final OS for CONTACT-02 trial in mCRPC

Presented By

Prof. Neeraj Agarwal, Huntsman Cancer Institute; University of Utah, UT, USA

Trial

Phase 3, CONTACT-02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:30

Full automation of prostate radiotherapy planning is feasible, but trust in systems remains a barrier

Expert

Mark Gooding

Journal

Oncology

17 September 2024 09:59

Metformin does not prevent progression of low-risk prostate cancer

Presented By

Dr Anthony Joshua, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, MAST

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:46

Baseline ctDNA has both prognostic and predictive value in mCRPC

Presented By

Prof. Johann de Bono, Royal Marsden Hospital, UK

Trial

Phase 3, PSMAfore

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:44

Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT

Presented By

Dr Brad Stish, Mayo Clinic, MN, USA

Trial

Phase 2, Alliance 222001

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:41

Interview: PMSA PET-CT offers patients with prostate cancer a more precise diagnosis

Expert

Dr Christopher DiBlasio, Genesis Care, Fort Myers, FL, USA

11 October 2023 10:28

Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC

Presented By

Prof. Karim Fizazi, Institute Gustave Roussy, France

Trial

Phase 3, TALAPRO-2

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:24

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By

Prof. Gerhardt Attard, UCL Cancer Institute London, UK

Trial

Phase 3, STAMPEDE

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:23

Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer

Presented By

Prof. Chris Parker, The Royal Marsden Hospital, UK

Trial

RADICALS-HD

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:17

Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer

Presented By

Dr Rahul Aggarwal, University of California San Francisco, CA, USA

Trial

Phase 3, PRESTO

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:13

177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC

Presented By

Prof. Michael Hofman, Peter McCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:08

Enzalutamide performs well in metastatic hormone-sensitive prostate cancer

Presented By

Prof. Ian Davis, Monash University, Australia

Trial

Phase 3, ENZAMET

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:04

Does systematic biopsy add value to the detection rate of prostate cancer?

Presented By

Dr Enrico Checcucci, University of Turin, Italy

Conference

EAU 2022

Type

News article

22 July 2022 12:42

PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer

Presented By

Prof. Lih-Ming Wong, University of Melbourne, Australia

Trial

Phase 3

Conference

EAU 2022

Type

News article

22 July 2022 12:41

Prostate cancer treatments reduce quality of life

Presented By

Mr André Deschamps, Europa Uomo, Belgium

Trial

EUPROMS 2.0

Conference

EAU 2022

Type

News article

22 July 2022 12:39

PROpel: Good results for abiraterone plus olaparib in mCRPC

Presented By

Prof. Noel Clarke, University of Manchester, UK

Trial

Phase 3, PROpel

Conference

EAU 2022

Type

News article

22 July 2022 12:37

Neoadjuvant hormonal therapy promising in high-risk prostate cancer

Presented By

Prof. Steven Joniau, UZ Leuven, Belgium

Trial

Phase 2, ARNEO

Conference

EAU 2022

Type

News article

22 July 2022 12:35

Darolutamide performs well across subgroups in mHSPC

Presented By

Prof. Bertrand Tombal, Université Catholique de Louvain, Belgium

Trial

Phase 3, ARASENS

Conference

EAU 2022

Type

News article

22 July 2022 12:33

First-line treatment with olaparib significantly improves PFS in mCRPC

Presented By

Dr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada

Trial

Phase 3, PROpel

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC

Presented By

Dr Kim Chi, University of British Columbia, Canada

Trial

Phase 3, MAGNITUDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

Darolutamide improves OS in mHSPC

Presented By

Dr Matthew Smith, Massachusetts General Hospital Cancer Center, MA, USA

Trial

Phase 3, ARASENS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Presented By

Dr Axel Merseburger, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PRESIDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence

Presented By

Dr David Schuster, Emory University School of Medicine, GA, USA

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel

Presented By

Prof. Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:23

Artificial intelligence improves prediction of long-term outcomes

Presented By

Dr Osama Mohamad, University of California San Francisco, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By

Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada

Trial

Phase 2, ACDC-RP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity

Presented By

Dr Xin Gao, Massachusetts General Hospital, MA, USA

Trial

Phase 2, ARDENT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

ASCO GU 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GU 2022

14 March 2022 07:21

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial

Phase 3, PEACE-1, STAMPEDE, ARCHES

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:27

EAU TV: Robotic surgery and advanced prostate cancer

Presented By

Prof. Maarten Albersen; Prof. Mottrie; Prof. Fizazi; Prof. Gillessen

Trial

VISION

Conference

EAU 2021

31 August 2021 12:15

EAU TV: The best on prostate cancer and incontinence & andrology

Presented By

Prof. Peter Albers; Prof. James N’Dow; Prof. Nicolas Mottet; Prof. Monique Roobol; Prof. Jens Sønksen; Prof. Francisco Cruz

Conference

EAU 2021

31 August 2021 12:15

Best of EAU: Updates on imaging and treatment of prostate cancer

Presented By

Prof. Alberto Briganti, IRCCS Ospedale San Raffaele, Milan, Italy

Trial

STHLM3MRI, TITAN

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:15

Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Presented By

Prof. Karim Fizazi, University of Paris-Saclay, Villejuif, France

Trial

Phase 3, PEACE-1

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:15

177Lu-PSMA-617: A new class of effective therapy

Presented By

Prof. Johann de Bono; Prof. Michael Hofman

Trial

VISION, TheraP

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:15

VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC

Presented By

Dr Michael Morris, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, VISION

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:18

Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC

Presented By

Dr Karim Fizazi , Institut Gustav Roussy, France

Trial

Phase 3, PEACE-1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:19

Lu177 as a promising new therapy for metastatic prostate cancer

Presented By

Dr Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Role of prostate cancer genomics is evolving

Presented By

Dr Ashley Ross, Feinberg School of Medicine, Northwestern University, Chicago, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Apalutamide prolongs progression-free survival in prostate cancer

Presented By

Dr Dana Rathkopf, Memorial Sloan Kettering Cancer Center, New York, USA

Trial

Phase 3, ACIS

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer

Presented By

Prof. Pirus Ghadjar, Charité Universitätsmedizin Berlin, Germany

Trial

Phase 3, SAKK 09/10

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:48

Intrinsic tumour biology may be predictive of treatment response in prostate cancer

Presented By

Prof. Felix Feng, University of California San Francisco, USA

Trial

Phase 3, SPARTAN

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:46

Final TITAN trial results favour use of apalutamide

Presented By

Dr Kim Chi, British Columbia Cancer and Vancouver Prostate Centre, Canada

Trial

Phase 3, TITAN

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:46

Abiraterone in M1 hormone-naïve prostate cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:51

New treatment option for patients with mCRPC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:50

Minimizing post-operative stress urinary incontinence after HoLEP: Our preliminary experience and short-term results of ‘’En Bloc’’ technique with early apical release

Presented By

Dr A. Tuccio, Careggi Hospital, University of Florence, Italy

Conference

EAU 2020

16 September 2020 16:28

Transperineal laser ablation of prostate

Presented By

Dr G.D. De Rienzo, Azienda Ospedaliera Policlinico di Bari, Italy

Conference

EAU 2020

16 September 2020 16:21

Prostatectomy: R-LRPE better than LRPE for continence

Principal Investigator

Prof. Jens-Uwe Stolzenburg , University of Leipzig, Germany

Trial

LAP-01

Conference

EAU 2020

Type

Peer-reviewed article

21 August 2020 14:49

PSMA PET-CT staging is 27% more accurate

Principal Investigator

Prof. Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

ProPSMA

Conference

EAU 2020

Type

Peer-reviewed article

21 August 2020 14:40

Docetaxel + hormonal therapy: improved prostate cancer PFS

Presented By

Dr Andreas Josefsson , Sahlgrenska University Hospital, Sweden

Trial

Phase 3, SPCG-14

Conference

EAU 2020

Type

Peer-reviewed article

21 August 2020 14:34

ARAMIS subgroup analysis: darolutamide benefits across PSADT groups

Principal Investigator

Prof. Martin Bögemann, University of Münster, Germany

Trial

Phase 3, ARAMIS

Conference

EAU 2020

Type

Peer-reviewed article

21 August 2020 13:42

Large patient-driven survey reveals QoL issues after prostate cancer treatment

Presented By

Mr André Deschamps , Europa Uomo, Belgium

Trial

EUPROMS

Conference

EAU 2020

Type

Peer-reviewed article

20 August 2020 13:05

Targeting steroid sulphatase in resistant prostate cancer cells

Presented By

Prof. Allen C. Gao , University of California Davis, USA

Conference

EAU 2020

Type

Peer-reviewed article

20 August 2020 13:00

Good tolerance of post-RP radiotherapy ± short-term ADT

Presented By

Dr Paul Sargos , Institut Bergonié, France

Trial

Phase 2, GETUG-AFU 22

Conference

EAU 2020

Type

Peer-reviewed article

20 August 2020 12:54

PARP inhibition in selected patients slows progression on advanced prostate cancer

Presented By

Prof. Maha Hussain, Northwestern University, Chicago, USA

Trial

Phase 3, PROfound

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 21:24

Third-line in mCRPC: CARD trial

Presented By

Prof. Ronald De Wit, Erasmus University Rotterdam, the Netherlands

Trial

CARD

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 20:24

Prostate cancer: spare radiotherapy after surgery

Presented By

Prof. Chris Parker, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK

Trial

RADICALS-RT

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 18:24

Enzalutamide offers survival advantage over other NSAAs in mHSPC

Presented By

Dr Christopher Sweeney, Dana-Farber Cancer Institute, USA

Trial

ENZAMET, TITAN

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 23:26

Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer

Presented By

Dr Kim N. Chi, BC Cancer Agency, Canada

Trial

Phase 3, TITAN

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 22:28

Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer

Presented By

Prof. Antonio Alcaraz, Prof. Noel Clarke

Trial

Phase 3, ARCHES

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 23:59

Prostate cancer active surveillance: Better patient risk stratification and use of imaging

Presented By

Dr Todd Morgan, Dr Vasilis Stavrinides, Dr Marco Bandini

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 22:03

Testosterone replacement therapy: Safe and maybe even protective

Presented By

Prof. Thomas Ahlering, Dr Maxwell Towe, Ribeiro Morgado

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 21:36

The role of pelvic lymph node dissection in prostate cancer: Extended vs standard

Presented By

Dr Karim Touijer, Dr Akshay Sood

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 21:10

When to use imaging and imaging-guided therapies

Presented By

Dr Lorenzo Bianchi, Dr Carlo Andrea Bravi

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 20:53

Cytoreductive radical prostatectomy: LoMP trial results

Trial

LoMP

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 18:24

Prostate cancer: What to expect the next 12 months

Trial

STAMPEDE, ENZAMET

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 10:27